Medline Shorts Retreat Before Q3 Print, But the Stock Keeps Falling

MDLN has lost 8.2% over the past month to close at $32.12, a steeper drop than nearly every name in its peer group, and the company reports Q3 results on November 4 with short sellers quietly covering even as the stock slides.

The short-covering story is the sharpest data point heading into the print. Short interest has fallen 35% over the past week and 28% over the past month, dropping to roughly 32.7 million shares. The ORTEX short score has also retreated sharply, from 64.8 on October 19 to 53 by October 29, reflecting a significant pullback in bearish conviction. Borrow conditions reinforce that: cost to borrow is a low 0.53%, down 13% on the week, and availability sits at 369% of short interest, well above the 52-week low of 161%, meaning the lending market is loose and there is no sign of a squeeze. Shorts are leaving, but not because bulls are pressing the other side.

Options positioning tells a different story. The put/call ratio has drifted lower to 1.02, running about 1.2 standard deviations below its 20-day average of 1.11. That is a modest shift toward calls relative to recent history, though puts still outnumber calls outright. The stock has moved against most of its correlated peers on both timeframes: MDLN fell 5.8% over the past week, while XRAY gained 1.1% and PODD was roughly flat. LMAT and KRMD also fell, but by less.

The Street remains broadly constructive but has been trimming targets persistently since the August print, when MDLN fell 17.9% on the day and extended that to a 15.6% loss over the following five sessions. Mizuho cut its target to $45 from $48 on October 22 while keeping an Outperform rating. Barclays and UBS both moved to $43 in September, also maintaining positive ratings. JPMorgan lowered its target from $53 to $46 in August. The consensus mean now stands at $44.31, implying roughly 38% upside from the current price. The bull case centres on Medline's scale, vertically integrated model, and $659 million of new business signed in the first half of 2026, with organic sales up 11.5% in Q2. The bear case is more immediate: roughly two-thirds of an estimated $200 million cost increase is expected to land in Q4, Medicaid exposure creates demand risk under potential BBBA-related cuts, and a heavy debt load limits room for error.

The ownership register adds an important dimension. GIC Private Limited, Singapore's sovereign wealth fund, sold approximately $997 million worth of MDLN shares across six tranches between October 2 and October 8, none under a 10b5-1 plan. Its institutional holding has since been reported at 85.9 million shares, down from a prior disclosure of around 114 million. GIC filed an updated Schedule 13G/A on October 30, bringing its disclosed stake to 13%, down from 14.6%. Carlyle Group and Blackstone together still account for roughly 38% of shares, and the sponsor-heavy register means a relatively small public float absorbs the selling pressure from GIC's exit. ORTEX puts the probability of MDLN joining the Nasdaq-100 at the December 2026 Annual Review at 38%, with the stock needing a 4.1% gain to close above the $33.31 entry line by the November 30 rank date. That mechanical bid is real but contingent on a price recovery this month.

The November 4 print will test whether management can narrow the gap between strong top-line growth and the mounting cost pressures that produced last quarter's 18% single-day drop, and whether the guidance frame for Q4 leaves the GIC selling looking prescient or premature.